You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Boston Scientific says drug-coated balloons could take up to 30% of the PCI market, TCAR is expected to return to double-digit growth, and the expanded interventional therapies division aspires to high single digits, aspire to double digits.
Boston Scientific reported third-quarter 2026 net sales of 5,138, up 1.5%, but net income attributable to common stockholders declined 22.9% to 582 after an August 2026 cybersecurity incident disrupted manufacturing and order fulfillment. Nine-month net sales rose 6.7% to 15,784.
Boston Scientific's Q3 sales grew 1.5% and adjusted EPS fell 3% to $0.73; a cyber incident cut growth approximately 300 basis points. Q4 guidance calls for minus 1 to minus 3 percent revenue and 77 cents to 79 cents adjusted EPS.
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5 percent, GAAP EPS of $0.40 and adjusted EPS of $0.73; it now estimates full-year adjusted EPS of $3.16 to $3.18 and fourth-quarter sales declining approximately (3.0) to (1.0) percent.
Boston Scientific Corp appointed Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer effective January 1, 2027, when it will establish three reportable segments, and appointed Mark Bickel Chief Accounting Officer effective March 1, 2027, succeeding Emily Woodworth.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 revenue and adjusted EPS missed guidance, the cybersecurity incident reduced growth and earnings, and Q4 organic revenue is now guided to decline 1% to 3%. Boston Scientific is pursuing over $500 million of restructuring savings and expects 2027 to be the trough before improved revenue and adjusted EPS growth in 2028 and 2029, while 2027 growth and margins, pipeline delays, and Penumbra dilution remain material headwinds.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Watchman net sales | $482M | FY2026 Q3 | -5.9% |
|
|
|||
| Adjusted net income (loss) non-GAAP | $1.28B | the three months ended June 30, 2026 filing | — |
| Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measu non-GAAP | 1.28B | the three months ended June 30, 2026 filing | — |
| Adjusted net income (loss) per common share — diluted (non-GAAP measure) non-GAAP | $0.86 | the three months ended June 30, 2026 filing | — |
| Adjusted net income (loss) per share non-GAAP | $0.86 | the three months ended June 30, 2026 filing | — |
| Segment operating income | $598M | the three months ended June 30, 2026 (MedSurg) filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BSX
this stock
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
EW
Edwards Lifesciences Corp
|
$61.61B | +25.7% | +11.5% | 60.5 | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Boston Scientific says drug-coated balloons could take up to 30% of the PCI market, TCAR is expected to return to double-digit growth, and the expanded interventional therapies division aspires to high single digits, aspire to double digits.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BSX | +3.7% | -0.1% | -23.1% | +5.6% | -53.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.1% | +1.1% | -23.6% | +5.8% | -64.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
